Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus paracasei LP-33
- Development stage
- Unknown
- Lead developer
- Chr. Hansen
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus paracasei LP-33 is a probiotic bacterial strain, recently reclassified as Lacticaseibacillus paracasei LP-33, that is primarily utilized for its immunomodulatory properties. It is developed and marketed by Uni-President Enterprises Corp, particularly in the form of functional dairy products and dietary supplements. The strain is hypothesized to alleviate allergic symptoms by modulating the balance between Th1 and Th2 immune responses, specifically by inducing the production of anti-inflammatory cytokines such as IL-10 and IFN-gamma while reducing the levels of allergen-specific IgE. Clinical research, including the NCT01096615 trial, has focused on its efficacy in managing persistent allergic rhinitis and atopic dermatitis, often as an adjunct to standard H1-antihistamine therapy.
- Brand names
- LP33LP-33LP 33
- Other names
- Lacticaseibacillus paracasei LP-33Lactobacillus paracasei strain LP-33L. paracasei LP-33
02
Targets
IL10 (Interleukin-10)IFNG (Interferon gamma)IgE (Immunoglobulin E)
Beyond the preview
Go deeper on lactobacillus paracasei LP-33.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus paracasei LP-33.